Sweden's Medivir to sell generics unit; PharMerica adopts poison pill after Omnicare offer;

@FiercePharma: Merck's discount offer to NICE wins OK for anti-TNF drug Simponi. Piece | Follow @FiercePharma

> Sweden's Medivir agreed to sell a generics subsidiary BMM Pharma, acquired in its BioPhausia buyout earlier this year, to Bluefish Pharmaceuticals for 38 million krona in cash and inventory, or about $9 million. Medivir release

> PharMerica adopted a poison pill to ward off hostile takeovers after receiving a $441 million bid from larger rival Omnicare ($OCR) earlier this week. Item

> AstraZeneca ($AZN) bought more than 1 million shares for 2826 pence per share as part of its ongoing buyback program. News

> Hi-Tech Pharmacal acquired marketing rights to an ANDA from KVK-Tech for an allergy drug to be marketed under the Lodrane brand name. Hi-Tech release

> UBS cut its target price for Hikma to 850 pence after first half earnings failed to live up to forecasts. Article

Biotech News

@FierceBiotech: Report: Samsung to test genomic analysis service. Item | Follow @FierceBiotech

@JohnCFierce: FDA approves Firazyr (Shire) for HAE. News | Follow @JohnCFierce

@RyanMFierce: Furiex Pharmaceuticals snags $15M loan to advance pipeline, including antibiotic, IBC drug and statin Article | Follow @RyanMFierce

@MaureenFierce: CDC: Teen HPV vaccination rates lagging. Article | Follow @MaureenFierce

> Study: Cancer trial participation less than 1%. Report

> J&J's XR pain drug gets FDA nod. Piece

> Gene therapy breaks 'bubble boy disease.' Article

> Medivir deals generics biz amid HepC drug trials. More

And Finally... The cost of treating obesity and related diseases is expected to add 2% to healthcare bills in the U.S. and U.K. by 2030. Report

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…